In a study investigating the interaction between EBV and COVID-19, conducted in Wuhan, China, it was found that 55.2% of patients hospitalized with COVID-19 had IgM antibodies against EBV (VCA), indicating possible reactivation of Epstein–Barr virus [14]. Here, CD40LG is linked to COVID-19.